BLTE

Belite Bio Inc ADR

Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.

Belite Bio Inc ADR (BLTE) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (C+); its weakest is Revisions (C-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.4 / 5.0
C
Value
C+
Factor Score 2.7 / 5.0
Growth
C
Factor Score 2.3 / 5.0
Profitability
C+
Factor Score 2.8 / 5.0
Momentum
C
Factor Score 2.4 / 5.0
Revisions
C-
Factor Score 1.9 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 0.0
EV / EBITDA -35.6
Rev Growth YoY 0.0%
Gross Margin N/A
Price Return 3M 1.8%
Price Return 12M 139.3%
Catalyst Signal 0.00
Market Cap N/A
TTM Revenue N/A
Price / Sales 0.0
ROE -18.9%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-08-05 C+ (2.7) C (2.3) C+ (2.8) C (2.4) C- (1.9) C (2.4)
2026-08-04 C+ (2.7) C (2.3) C+ (2.8) C (2.4) C- (1.9) C (2.4)
2026-08-03 C+ (2.7) C (2.4) C- (2.1) C (2.4) C- (2.0) C (2.3)
2026-08-02 C+ (2.7) C (2.4) C- (2.1) C (2.4) C- (1.9) C (2.3)